Eatontown, NJ – June 3, 2015 — American CryoStem Corporation (OTCQB: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the addition of Dr. KiBum Lee to the Medical & Scientific Advisory Board.
Dr. KiBum Lee will be assisting CRYO in further developing its adipose derived stem cell platform in combination with complementary technologies aimed at development of an easy, effective, and non-toxic methodology to control differentiation into specific cell lineages. Dr. Lee’s team has recently focused on developing a variety of technologies to selectively control the differentiation of stem cells towards specific cell lineages (e.g. neurons, oligodendrocytes, chondrocytes, osteocytes, and adipocytes). Since early 2013, Dr. Lee has included CRYO’s ATCELL, single donor cell lines and ACSelerate, Cell Culture and Differentiation mediums, in his research efforts and shown positive results in the differentiation of CRYO’s ATCELL cell lines.
On December 1, 2013 the company entered into a Cooperative Research Agreement and a Research Evaluation and License Option Agreement with Rutgers, The State University of New Jersey covering our collaborative efforts. During the course of our mutual efforts, Dr. Lee and his staff have published the results in Advanced Biomaterials “NanoScript: A Nanoparticle-Based Transcription Factor for Effective Gene Regulation and Stem Cell Differentiation” leading to a new joint patent filing in 2014 and recently published in ACS Nano (2015) “Graphene Oxide Patterned Substrates for Controlling Adipose-Derived Stem Cell Differentiation” which resulted in an addition patent filing USPTO Application No: 62/139,565 covering the new technology.
Dr. Lee stated, “Joining the Scientific Advisory Board of American CryoStem is a great opportunity for me to become more involved with the Company’s current stem cell platform and patented differentiation mediums, as well as be a part of their ongoing global growth and research efforts. This relationship affords me the ability to provide greater input and scientific guidance to the Company supporting the commercialization effort of their products and our mutual work.”
John Arnone , CEO of American CryoStem remarked, “The addition of Dr. Lee, a noted and well respected New Jersey based scientist solidifies our relationship and commitment to working within the robust scientific community in New Jersey. Following the success of our initial collaborative efforts within the university model working with Dr Lee, we plan to continue our efforts to optimize and commercialize our products that support the full therapeutic potential of stem cells. Our focus is to continue developing new cellular technologies, intellectual property, and product commercialization strategies.”
About Dr. KiBum Lee: Dr. Lee is an associate professor of Chemistry and Chemical Biology at Rutgers University, where he has been a faculty member since 2008. He received his Ph.D. in Chemistry from Northwestern University (with Chad. A. Mirkin; 2004) and completed his postdoctoral training at The Scripps Research Institute (with Peter G. Schultz; 2007). The primary research interest of Dr. Lee’s team is the study and development of and integrated nanotechnologies and chemical functional genomics to modulate signaling pathways in mammalian cells towards specific cell lineages or behaviors. In particular, his team is exploring critical problems in cancer biology and stem cell biology pertaining to the cellular –micro- environmental interactions, and discovering how to control these interactions at the subcellular and single cell level using chemical biology and nanotechnology. From this research effort, he has developed technology platforms that may overcome the critical barriers to harnessing the full therapeutic potential of stem cells.
In recognition of his outstanding scientific achievement at Rutgers, Dr. Lee has received several awards including NIH Director’s New Innovator Awards (2009), Board of Trustees Research Award for Scholarly Excellence (2013), Burroughs Wellcome Fund Collaborative Research Grant Award (2014), Busch Biomedical Grant Award (2013), New Jersey Spinal Cord Exploratory Research Award (2013), Johnson and Johnson Proof-of-Concept Award (2011), Faculty Research Grant Award (2012), New Jersey Spinal Cord Research Award (2009), and Grant Proposal Development Award (2008). He is the first author, co-author, and corresponding author of approximately 45 articles published in high-profile journals including Science, Cell Stem Cell, J. Am. Chem. Soc., Angew. Chem, Int. Ed., Nano Letters, ACS Nano, Advanced Materials, Biomaterials, Scientific Reports, Lab Chip, Small, Phys. Chem. Chem. Phys., Nanomedicne, and Cancer Research, which are highly cited (>5000). [Total 55 publications, 5000 citations, h-index: 23; 15 Patents/applications]
About American CryoStem Corporation
Founded in 2008, American CryoStem is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of Regenerative and Personalized Medicine. The Company has developed Standard Operating Procedures (SOPs) to operate a state-of-art, FDA-registered, clinical laboratory dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs). Leveraging platform technologies with 5+ developed products the Company is creating a global footprint of licensed laboratory affiliates and physicians networks to deliver current and future cellular applications.
The Company maintains a strategic portfolio of intellectual property that forms its standardized platform which supports a growing pipeline of stem cell applications and biologic products. The Company’s R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC products by combining its platform with synergistic technologies to create jointly developed applications and intellectual property.
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.